{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:57:43Z","timestamp":1760147863500,"version":"build-2065373602"},"reference-count":32,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCDD"],"abstract":"<jats:p>Background: To compare the characteristics of a \u201creal world\u201d population included in a prospective registry to patients enrolled in a randomized, controlled trial (RCT) after endovascular revascularization (EVR) for symptomatic peripheral artery disease (PAD). Methods: The RECcording COurses of vasculaR Diseases (RECCORD) registry is an observational registry prospectively recruiting patients undergoing EVR for symptomatic PAD in Germany. VOYAGER PAD was an RCT which demonstrated the superiority of rivaroxaban and aspirin versus aspirin to reduce major cardiac and ischemic limb events following infrainguinal revascularization for symptomatic PAD. For this exploratory analysis, the clinical characteristics of 2.498 patients enrolled in RECCORD and of 4.293 patients from VOYAGER PAD who underwent EVR were compared. Results: The rate of patients aged \u2265 75 years was considerably higher in the registry (37.7 vs. 22.5%). More patients in the registry had undergone previous EVR (50.7 vs. 38.7%) or suffered from critical limb threatening ischemia (24.3 vs. 19.5%). Registry patients were more commonly active smokers (51.8 vs. 33.6%), but less frequently suffered from diabetes mellitus (36.4 vs. 44.7%). While statins (70.5 vs. 81.7%) were less frequently used, antiproliferative catheter technologies (45.6 vs. 31.4%) and postinterventional dual antiplatelet therapy (64.5 vs. 53.6%) were more commonly applied in the registry. Conclusions: There were many similarities but some clinically meaningful differences in clinical characteristics between PAD patients who underwent EVR and were included in a nationwide registry and PAD patients from the VOYAGER PAD trial.<\/jats:p>","DOI":"10.3390\/jcdd10030115","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T03:35:42Z","timestamp":1678419342000},"page":"115","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient Characteristics in the Recording Courses of Vascular Diseases (Reccord) Registry: Comparison with the Voyager Pad Endovascular Cohort"],"prefix":"10.3390","volume":"10","author":[{"given":"Michael","family":"Czihal","sequence":"first","affiliation":[{"name":"Division of Vascular Medicine, Medical Clinic and Policlinic IV, Hospital of the Ludwig-Maximilians-University, Ziemssenstra\u00dfe 5, 80336 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9912-2814","authenticated-orcid":false,"given":"Nasser","family":"Malyar","sequence":"additional","affiliation":[{"name":"Department of Cardiology I\u2014Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital, 48149 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Stausberg","sequence":"additional","affiliation":[{"name":"Independent Researcher, 45276 Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Division of Vascular Medicine, Medical Clinic and Policlinic IV, Hospital of the Ludwig-Maximilians-University, Ziemssenstra\u00dfe 5, 80336 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e1020","DOI":"10.1016\/S2214-109X(19)30255-4","article-title":"Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: An updated systematic review and analysis","volume":"7","author":"Song","year":"2019","journal-title":"Lancet. Glob. Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","article-title":"2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: The European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS)","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jacc.2019.11.050","article-title":"Long-Term Outcomes and Associations With Major Adverse Limb Events After Peripheral Artery Revascularization","volume":"75","author":"Hess","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e009584","DOI":"10.1161\/CIRCINTERVENTIONS.120.009584","article-title":"Contemporary Review of Antithrombotic Therapy in Peripheral Artery Disease","volume":"13","author":"Hess","year":"2020","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in Peripheral Artery Disease after Revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1024\/0301-1526\/a000882","article-title":"Demographic and procedural characteristics in the RECording COurses of vasculaR Diseases (RECCORD) registry\u2014The first 1000 patients","volume":"49","author":"Malyar","year":"2020","journal-title":"Vasa"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1024\/0301-1526\/a000631","article-title":"Rationale and design of the RECording COurses of vasculaR Diseases registry (RECCORD registry)","volume":"46","author":"Malyar","year":"2017","journal-title":"Vasa"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Stella, J., Stausberg, J., Lichtenberg, M., Hoffmann, U., and Malyar, N.M. (2022). Clinical Characteristics and Current Practice of Endovascular Revascularization in Aorto-Iliac, Femoropopliteal and Infra-Popliteal Lower Extremity Artery Disease-Insights from the RECCORD Registry. J. Clin. Med., 11.","DOI":"10.3390\/jcm11206074"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ahj.2018.01.011","article-title":"Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD)","volume":"199","author":"Capell","year":"2018","journal-title":"Am. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jvs.2006.12.037","article-title":"Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)","volume":"45","author":"Norgren","year":"2007","journal-title":"J. Vasc. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/j.jacc.2021.08.052","article-title":"Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD","volume":"78","author":"Hess","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e024279","DOI":"10.1161\/JAHA.121.024279","article-title":"Cardiovascular and Limb Events Following Endovascular Revascularization Among Patients \u226565 Years Old: An American College of Cardiology PVI Registry Analysis","volume":"11","author":"Weissler","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e010635","DOI":"10.1161\/CIRCINTERVENTIONS.121.010635","article-title":"Differences Between Patients With Intermittent Claudication and Critical Limb Ischemia Undergoing Endovascular Intervention: Insights From the Excellence in Peripheral Artery Disease Registry","volume":"14","author":"Patel","year":"2021","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ejvs.2022.05.038","article-title":"Prediction Models for Two Year Overall Survival and Amputation Free Survival After Revascularisation for Chronic Limb Threatening Ischaemia","volume":"64","author":"Miyata","year":"2022","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.avsg.2021.10.068","article-title":"Rates of Intervention for Claudication versus Chronic Limb-Threatening Ischemia in Canada and United States","volume":"82","author":"Li","year":"2022","journal-title":"Ann. Vasc. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jvs.2020.08.032","article-title":"Systematic review and meta-analysis of outcomes of lower extremity peripheral arterial interventions in patients with and without chronic kidney disease or end-stage renal disease","volume":"73","author":"Sheikh","year":"2021","journal-title":"J. Vasc. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ejvs.2018.09.025","article-title":"Editor\u2019s Choice\u2014Infrainguinal Bypass Following Failed Endovascular Intervention Compared With Primary Bypass: A Systematic Review and Meta-Analysis","volume":"57","author":"Hossain","year":"2019","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5935039","DOI":"10.1155\/2022\/5935039","article-title":"Endovascular Treatment and Outcomes for Femoropopliteal In-Stent Restenosis: Insights from the XLPAD Registry","volume":"2022","author":"Vu","year":"2022","journal-title":"J. Interv. Cardiol."},{"key":"ref_19","first-page":"285","article-title":"Revascularisation for Symptomatic Peripheral Artery Disease: External Applicability of the VOYAGER PAD Trial","volume":"63","author":"Nielsen","year":"2021","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100113","DOI":"10.1016\/j.lanepe.2021.100113","article-title":"Peripheral artery disease in Germany (2009-2018): Prevalence, frequency of specialized ambulatory care and use of guideline-recommended therapy\u2014A population-based study","volume":"5","author":"Rammos","year":"2021","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e011245","DOI":"10.1161\/JAHA.118.011245","article-title":"Risk of Death Following Application of Paclitaxel-Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"7","author":"Katsanos","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1093\/eurheartj\/ehz698","article-title":"Mortality after use of paclitaxel-based devices in peripheral arteries: A real-world safety analysis","volume":"41","author":"Freisinger","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_23","first-page":"755","article-title":"Mortality Rates After Paclitaxel-Coated Device Use in Patients With Occlusive Femoropopliteal Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"28","author":"Dinh","year":"2021","journal-title":"J. Endovasc. Ther. Off. J. Int. Soc. Endovasc. Spec."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s42155-019-0079-8","article-title":"The CLEAR (Considering Leading Experts\u2019 Antithrombotic Regimes around peripheral angioplasty) survey: An international perspective on antiplatelet and anticoagulant practice for peripheral arterial endovascular intervention","volume":"2","author":"Wong","year":"2019","journal-title":"CVIR Endovasc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1093\/eurheartj\/ehab390","article-title":"Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: A consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy","volume":"42","author":"Aboyans","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1161\/CIRCULATIONAHA.120.050465","article-title":"Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety","volume":"142","author":"Hiatt","year":"2020","journal-title":"Circulation"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/eurheartj\/ehq021","article-title":"Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis","volume":"31","author":"Ducrocq","year":"2010","journal-title":"Eur. Heart J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: A pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ejvs.2021.12.019","article-title":"The OAC(3)-PAD Risk Score Predicts Major Bleeding Events one Year after Hospitalisation for Peripheral Artery Disease","volume":"63","author":"Behrendt","year":"2022","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jama.2009.1092","article-title":"Registries for robust evidence","volume":"302","author":"Dreyer","year":"2009","journal-title":"Jama"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"29597","DOI":"10.3402\/gha.v9.29597","article-title":"Doubly blind: A systematic review of gender in randomised controlled trials","volume":"9","author":"Phillips","year":"2016","journal-title":"Glob. Health Action"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jclinepi.2017.09.017","article-title":"Registry-based randomized Control. trials merged the strength of randomized controlled trails and observational studies and give rise to more pragmatic trials","volume":"93","author":"Mathes","year":"2018","journal-title":"J. Clin. Epidemiol."}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/10\/3\/115\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:51:51Z","timestamp":1760122311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/10\/3\/115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,10]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["jcdd10030115"],"URL":"https:\/\/doi.org\/10.3390\/jcdd10030115","relation":{},"ISSN":["2308-3425"],"issn-type":[{"type":"electronic","value":"2308-3425"}],"subject":[],"published":{"date-parts":[[2023,3,10]]}}}